Colgate-Palmolive Company (NYSE:CL) reported the Q2 2025 earnings with signs of resilient growth despite challenges. A modest increase in net income of 0.8% shows the company's ability to perform under pressure. Despite beating earnings expectations, Q2 came with margin pressures persisting, causing adjustment in the 2025 guidance. Successful Q2 results saw an increase in positions by various investment firms such as Natixis Advisors LLC, TCW Group Inc, Mackenzie Financial Corp and others. Despite the company's careful outlook on future growth, the average rating from analysts stays at 'Moderate Buy'. However, shares hit a new 52-Week low indicating future uncertainties. The company announced a robust three-year productivity program to bolster growth, yet Q2 earnings preview showed a downside risk due to declining EPS and revenue expectations. Restructuring plans are taking shape as the company seeks to improve its position in the market. As per hedge funds, it emerges as a good skincare stock to invest in. It has proven to be a strong momentum stock, despite some insider disposing off their stocks.
Colgate-Palmolive Company CL News Analytics from Sat, 01 Mar 2025 08:00:00 GMT to Sat, 02 Aug 2025 19:30:47 GMT - Rating 1 - Innovation 3 - Information 6 - Rumor -5
